TY - JOUR
T1 - A phase I study of gemcitabine plus irinotecan for advanced NSCLC
T2 - Japan Clinical Oncology Group trial (JCOG9904)
AU - Kurata, Takayasu
AU - Yamamoto, Nobuyuki
AU - Komiya, Takefumi
AU - Tsurutani, Junji
AU - Miyazaki, Masaki
AU - Tamura, Kenji
AU - Takeda, Koji
AU - Nakagawa, Kazuhiko
AU - Fukuoka, Masahiro
PY - 2010/6/3
Y1 - 2010/6/3
N2 - A combination Phase I study of gemcitabine and irinotecan in patients with previously untreated advanced non-small-cell lung cancer was conducted. Patients received gemcitabine and irinotecan on Days 1 and 8 every 3 weeks. A total of 11 patients were enrolled. Three of six patients who received the starting dose (gemcitabine, 800 mg/m.2; irinotecan, 80 mg/m. 2) experienced dose-limiting toxicities (Grade 4 neutropenia, Grade 3 elevation of transaminase and Grade 5 interstitial pneumonia). At the reduced dose level (gemcitabine, 800 mg/m. 2; irinotecan, 60 mg/m. 2), all two assessable patients could not meet the administration criteria of Day 8 (one, Grade 2 elevation of transaminase; the other, Grade 1 diarrhea). No objective response was observed in eight evaluable patients. We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies.
AB - A combination Phase I study of gemcitabine and irinotecan in patients with previously untreated advanced non-small-cell lung cancer was conducted. Patients received gemcitabine and irinotecan on Days 1 and 8 every 3 weeks. A total of 11 patients were enrolled. Three of six patients who received the starting dose (gemcitabine, 800 mg/m.2; irinotecan, 80 mg/m. 2) experienced dose-limiting toxicities (Grade 4 neutropenia, Grade 3 elevation of transaminase and Grade 5 interstitial pneumonia). At the reduced dose level (gemcitabine, 800 mg/m. 2; irinotecan, 60 mg/m. 2), all two assessable patients could not meet the administration criteria of Day 8 (one, Grade 2 elevation of transaminase; the other, Grade 1 diarrhea). No objective response was observed in eight evaluable patients. We could not determine the recommended dose of this combination because of intolerable toxicities and no efficacy. Therefore, it is difficult to forward this combination chemotherapy toward further studies.
UR - http://www.scopus.com/inward/record.url?scp=77957694365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957694365&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyq079
DO - 10.1093/jjco/hyq079
M3 - Article
C2 - 20522445
AN - SCOPUS:77957694365
SN - 0368-2811
VL - 40
SP - 992
EP - 994
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 10
M1 - hyq079
ER -
